{
    "2021-06-14": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Here is What Hedge Funds Think About AbbVie Inc (ABBV)",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "AbbVie",
                        "Think"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock Sinks",
                        "Market Gains"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "I-Mab Seeks Multibillion-Dollar Cancer Drug Partnership",
                "features": {
                    "keywords": [
                        "I-Mab",
                        "Cancer Drug",
                        "Partnership"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients",
                "features": {
                    "keywords": [
                        "JNJ",
                        "Imbruvica",
                        "AbbVie",
                        "Venclexta",
                        "Progression-Free Survival",
                        "Leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}